Search

Your search keyword '"Biplab Dasgupta"' showing total 124 results

Search Constraints

Start Over You searched for: Author "Biplab Dasgupta" Remove constraint Author: "Biplab Dasgupta"
124 results on '"Biplab Dasgupta"'

Search Results

1. Chronic AMPK inactivation slows SHH medulloblastoma progression by inhibiting mTORC1 signaling and depleting tumor stem cells

2. Analysis of reactive astrogliosis in mouse brain using in situ hybridization combined with immunohistochemistry

3. Insight on Transcriptional Regulation of the Energy Sensing AMPK and Biosynthetic mTOR Pathway Genes

4. Supplementary Figures 1 - 4 from The AMPK Inhibitor Compound C Is a Potent AMPK-Independent Antiglioma Agent

5. Data from The AMPK Inhibitor Compound C Is a Potent AMPK-Independent Antiglioma Agent

7. Data from Direct Inhibition of Retinoblastoma Phosphorylation by Nimbolide Causes Cell-Cycle Arrest and Suppresses Glioblastoma Growth

8. Figure S3 from Activation of the Receptor Tyrosine Kinase AXL Regulates the Immune Microenvironment in Glioblastoma

9. Supplementary Figure 1 from Direct Inhibition of Retinoblastoma Phosphorylation by Nimbolide Causes Cell-Cycle Arrest and Suppresses Glioblastoma Growth

10. Data from Activation of the Receptor Tyrosine Kinase AXL Regulates the Immune Microenvironment in Glioblastoma

11. Supplementary figure legends from Activation of the Receptor Tyrosine Kinase AXL Regulates the Immune Microenvironment in Glioblastoma

12. Supplementary Figure 2 from Spatiotemporal Differences in CXCL12 Expression and Cyclic AMP Underlie the Unique Pattern of Optic Glioma Growth in Neurofibromatosis Type 1

13. Data from Glioma Formation in Neurofibromatosis 1 Reflects Preferential Activation of K-RAS in Astrocytes

14. Supplementary Figure 1 from Spatiotemporal Differences in CXCL12 Expression and Cyclic AMP Underlie the Unique Pattern of Optic Glioma Growth in Neurofibromatosis Type 1

15. Data from FOXD1–ALDH1A3 Signaling Is a Determinant for the Self-Renewal and Tumorigenicity of Mesenchymal Glioma Stem Cells

16. Supplementary Tables 1 through 3 from FOXD1–ALDH1A3 Signaling Is a Determinant for the Self-Renewal and Tumorigenicity of Mesenchymal Glioma Stem Cells

17. Supplementary Figures 1 through 7 from FOXD1–ALDH1A3 Signaling Is a Determinant for the Self-Renewal and Tumorigenicity of Mesenchymal Glioma Stem Cells

18. Supplementary Methods and Materials from FOXD1–ALDH1A3 Signaling Is a Determinant for the Self-Renewal and Tumorigenicity of Mesenchymal Glioma Stem Cells

20. Supplementary Legends 1-2 from Spatiotemporal Differences in CXCL12 Expression and Cyclic AMP Underlie the Unique Pattern of Optic Glioma Growth in Neurofibromatosis Type 1

21. Potentiation of temozolomide activity against glioblastoma cells by aromatase inhibitor letrozole

22. AMPK in the brain: its roles in glucose and neural metabolism

23. Bone marrow regeneration requires mitochondrial transfer from donor Cx43-expressing hematopoietic progenitors to stroma

24. EXTH-50. THE COMPLEXITIES OF FATTY ACID DESATURATION IN GLIOBLASTOMA

25. TMET-35. ONE CARBON AND NUCLEOTIDE METABOLISM ARE NOVEL TARGETS IN PEDIATRIC BRAINSTEM TUMORS

26. EXTH-101. MECHANISTIC INSIGHTS INTO CYTOTOXIC EFFECTS OF LETROZOLE AGAINST GLIOBLASTOMA CELLS

27. DIPG-03. Therapeutic targeting of purine biosynthesis in DIPG

28. Targeting Energy Metabolism to Overcome Therapeutic Resistance of Glioblastoma and Tumor-associated Edema

29. Analysis of reactive astrogliosis in mouse brain using in situ hybridization combined with immunohistochemistry

30. Mechanisms of stearoyl CoA desaturase inhibitor sensitivity and acquired resistance in cancer

31. AMP kinase promotes glioblastoma bioenergetics and tumour growth

32. EXTH-52. SYSTEMIC AND BRAIN PHARMACOKINETICS OF THE AMP-ACTIVATED PROTEIN KINASE SELECTIVE INHIBITOR SBI-0206965 AS A POTENTIAL THERAPEUTIC AGENT FOR THE TREATMENT OF GLIOBLASTOMA MULTIFORME

33. CSIG-11. KINASE-DIRECTED INHIBITION OF PYRIMIDINE BIOSYNTHESIS IN PTEN-DEFICIENT GLIOBLASTOMA

34. RARE-22. THERAPEUTIC TARGETING OF PURINE METABOLISM IN DIPG

35. Copb2 is essential for embryogenesis and hypomorphic mutations cause human microcephaly

36. The transcription factor Olig2 is important for the biology of diffuse intrinsic pontine gliomas

37. EXTH-40. THERAPEUTICALLY TARGETING DE NOVO PURINE BIOSYNTHESIS IN DIFFUSE INTRINSIC PONTINE GLIOMA

38. CBMT-05. GENETIC AND EPIGENETIC MECHANISMS REGULATING SCD INHIBITOR SENSITIVITY IN GLIOBLASTOMA

39. AMPK-Regulated Astrocytic Lactate Shuttle Plays a Non-Cell-Autonomous Role in Neuronal Survival

40. DDRE-09. THERAPEUTIC TARGETING OF PURINE METABOLISM IN DIPG

41. Serine/Threonine Kinase MLK4 Determines Mesenchymal Identity in Glioma Stem Cells in an NF-κB-dependent Manner

42. TAMI-55. THE EVOLUTIONARY ENIGMA OF FATTY ACID DESATURATION IN GLIOBLASTOMA

43. ACTR-20. A SMALL MOLECULE AXL INHIBITOR, BGB324 – FIRST-IN-HUMAN GBM SURGICAL PK TRIAL FOR RECURRENT TUMORS

44. Plasma and brain pharmacokinetics of letrozole and drug interaction studies with temozolomide in NOD-scid gamma mice and sprague dawley rats

45. Activation of the receptor tyrosine kinase AXL regulates the immune microenvironment in glioblastoma

46. Compound C/Dorsomorphin: Its Use and Misuse as an AMPK Inhibitor

47. Compound C/Dorsomorphin: Its Use and Misuse as an AMPK Inhibitor

48. Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition)

49. CSIG-31. PRE-CLINICAL STUDY AND CLINICAL DEVELOPMENT OF AXL-TARGETING THERAPY FOR RECURRENT GLIOBLASTOMA

50. TMOD-40. INTRACRANIAL PATIENT-DERIVED XENOGRAFT FROM A PEDIATRIC GLIOBLASTOMA RETAINS MOLECULAR CHARACTERISTICS AND GROWTH PATHWAYS

Catalog

Books, media, physical & digital resources